Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 1.00 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873431 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL358341 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL20873408 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL3838718 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL3837585 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL19553159 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL3838115 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL20873413 | 0.97 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL20880308 | 0.97 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 | |
| SCHEMBL3838750 | 0.97 | CAPN1 (1.00) | CAPN1CTSLCTSBCTSKHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114368-A1 | COMPOSITIONS AND METHODS RELATING TO PEDIATRIC NEUROMUSCULAR DISEASES AND NEUROGENERATIVE DISORDERS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2025-04-10 | — | — | US | claimed |
| WO-2024153744-A1 | AUTOPHAGY ACTIVATORS FOR THE TREATMENT OF RHABDOMYOLYSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-25 | — | — | WO | claimed |
| EP-3452034-B1 | CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING | FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) | 2024-05-15 | — | — | EP | claimed |
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | claimed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | claimed |
| EP-3969913-A1 | BIOMARKER FOR ASSESSMENT OF SPINAL CORD INJURY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2022-03-23 | — | — | EP | claimed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | claimed |
| US-20190125714-A1 | CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) | 2019-05-02 | — | — | US | claimed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | claimed |
| EP-3452034-A1 | CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca (ES) | 2019-03-13 | — | — | EP | claimed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | claimed |
| US-8697746-B2 | Solid dispersion of alpha-ketoamide derivatives | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2014-04-15 | — | — | US | claimed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | claimed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | claimed |
| EP-2593089-A1 | SOLID DISPERSION OF ALFA-KETOAMIDE DERIVATIVES | Senju Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | claimed |
| US-20120016020-A1 | SOLID DISPERSION OF ALPHA-KETOAMIDE DERIVATIVES | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | claimed |
| WO-2012008159-A1 | SOLID DISPERSION OF ALFA-KETOAMIDE DERIVATIVES | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | WO | claimed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | claimed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | claimed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | CAPN1 2767/4885CTSL 3697/4885CTSB 2800/4885 |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CAPN1 4158/4885CTSL 4677/4885CTSB 3143/4885 |
| US-20190125714-A1 | CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSL 149/4885CTSB 61/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSL 311/4885CTSB 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.